Medication info
Viban Tablet 80 mg (Valsartan)

Viban Tablet 80 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Kwangdong Pharmaceutical Co., Ltd.
Appearance
Light red round film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200809486 · Notified 2008.09.12 · Insurance code 641803990

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
* 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When co-administered with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; over the following weeks, increase the dose according to patient tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other post-myocardial infarction treatments (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, as there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Kwangdong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medication is effective for the treatment of hypertension and is used particularly in patients with essential hypertension. It also helps improve heart failure in patients who are intolerant to ACE inhibitors. After myocardial infarction, it is used in patients with left ventricular dysfunction to reduce the risk of mortality. Thus, it aids in blood pressure control and improvement of cardiac function, enhancing the overall cardiovascular health of patients.

How to take

Adult dose

* 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When co-administered with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; over the following weeks, increase the dose according to patient tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other post-myocardial infarction treatments (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, as there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with allergy to this medication or its components, in pregnant or lactating women, in patients with severe liver dysfunction, certain kidney diseases, or hereditary angioedema patients. Special caution should be taken in older adults or in patients with high serum potassium levels, weakened liver function, and those with heart disease when using this medication. Side effects such as dizziness, headache, fatigue, and cough may occur during the use of this medication, and in severe cases, hypotension or renal dysfunction may arise, so if symptoms occur, consult a doctor immediately. This medication may interact with other blood pressure medications, diuretics, and potassium-sparing drugs, so it is essential to inform healthcare providers of all medications currently being taken. Women who are pregnant or planning to become pregnant should avoid this medication, and it is also advisable not to use it while breastfeeding. The safety of this medication in children and adolescents has not been established, so it is not recommended for individuals under 18 years of age. For older adults, there is a risk of excessive hypotension; therefore, treatment should start at a low dose and the patient's condition must be monitored closely. In case of overdose, symptoms like severe hypotension or decreased consciousness may occur; seek medical attention immediately for appropriate treatment. This medication should be stored out of reach of children and should not be transferred to another container. If any unusual symptoms occur during treatment, consult healthcare providers for appropriate measures.

Side effects

  • Headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 53 more
  • colicky pain
  • nausea
  • pharyngitis
  • arthralgia
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • kidney dysfunction
  • hyperkalemia
  • angioedema
  • heart failure
  • vascular edema
  • erythema
  • pruritus
  • serum sickness
  • vasculitis
  • syncope
  • epistaxis
  • hepatitis
  • arrhythmia
  • intestinal vascular edema
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • vesicular dermatosis
  • decreased red blood cell volume
  • decreased hemoglobin
  • neutropenia
  • edema
  • weakness
  • insomnia
  • decreased libido
  • drowsiness
  • atrial fibrillation
  • vomiting
  • constipation
  • thirst
  • loss of appetite
  • lethargy
  • dyspepsia
  • anemia
  • tinnitus
  • tension headaches
  • decreased motor function
  • confusion
  • chest pain
  • rash
  • myalgia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture; therefore, it must be stored in a tightly sealed container. Additionally, it is crucial to keep it in a cool place below 30 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

Light red round film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.